Charles Tompkins, MD
Family Medicine · Luverne, ALNPI 1760418438
Payments from drug & device makers
Across 384 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$917
- Novo Nordisk$749
- AstraZeneca$673
- GSK$447
- Pfizer$446
- Otsuka America Pharmaceutical, Inc.$308
- plus $3K from 29 others
What the payments were for
- Food & beverage$6,252100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 63 | $917 |
| Novo Nordisk | 64 | $749 |
| AstraZeneca | 38 | $673 |
| GSK | 26 | $447 |
| Pfizer | 27 | $446 |
| Otsuka America Pharmaceutical, Inc. | 14 | $308 |
| Lilly USA, LLC | 20 | $287 |
| Johnson & Johnson | 14 | $262 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $233 |
| Novartis | 14 | $203 |
| Boehringer Ingelheim | 11 | $186 |
| Merck | 11 | $178 |
| Axsome Therapeutics, Inc. | 5 | $145 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $142 |
| Neurocrine Biosciences, Inc. | 6 | $124 |
| Amgen | 8 | $106 |
| Bayer | 4 | $95 |
| Sanofi-aventis U.S. LLC | 5 | $82 |
| Kowa Pharmaceuticals America, Inc. | 5 | $69 |
| Ardelyx, Inc. | 4 | $67 |
| E.r. Squibb & Sons, L.L.C. | 4 | $62 |
| Teva Pharmaceuticals USA, Inc. | 4 | $61 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $54 |
| Radius Health, Inc. | 2 | $53 |
| Daiichi Sankyo Inc. | 3 | $53 |
| Phathom Pharmaceuticals, Inc. | 3 | $52 |
| Dexcom, Inc. | 2 | $43 |
| Medtronic | 1 | $32 |
| Abbott | 1 | $24 |
| Lundbeck LLC | 1 | $22 |
| Insulet Corporation | 1 | $20 |
| Astellas Pharma US Inc | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$6,252 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 42 | $165,757 |
| EliquisApixaban | 191 | $78,855 |
| FarxigaDapagliflozin Propanediol | 196 | $62,654 |
| OzempicSemaglutide | 47 | $51,698 |
| LinzessLinaclotide | 52 | $41,147 |
| XifaxanRifaximin | 24 | $38,744 |
| JardianceEmpagliflozin | 85 | $33,394 |
| XareltoRivaroxaban | 106 | $33,126 |
| TrulicityDulaglutide | 29 | $28,285 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $26,525 |
| Pregabalin | 249 | $18,097 |
| RexultiBrexpiprazole | 24 | $15,549 |
| JanuviaSitagliptin Phosphate | 50 | $14,125 |
| Gabapentin | 1,033 | $12,846 |
| TrulancePlecanatide | 16 | $11,536 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $124 | $165,75742 claims |
| PfizerEliquis | $446 | $78,855191 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $673 | $77,753236 claims |
| Novo NordiskOzempic, Tresiba | $749 | $62,26076 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $142 | $50,28040 claims |
| AbbVieLinzess, Combigan | $917 | $46,40276 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $447 | $40,93567 claims |
| Boehringer IngelheimJardiance | $186 | $33,39485 claims |
| Johnson & JohnsonXarelto | $262 | $33,126106 claims |
| Lilly USA, LLCTrulicity | $287 | $28,28529 claims |
| MerckJanuvia, Belsomra | $178 | $19,71163 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $308 | $15,54924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Luverne
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.